Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price

investors.com/news/technology/novo-nordisk-stock-ceo-transition-eli-lilly-weight-loss-drugs/?src=A00220

said Friday it will replace Chief Executive Lars Fruergaard Jorgensen, citing a sharp tumble for Novo shares amid growing competition for its popular diabetes and obesity drugs Ozempic and Wegovy.
The drugmaker says Jorgensen will continue as CEO while the board searches for his…

This story appeared on investors.com, 2025-05-16 15:00:47.
The Entire Business World on a Single Page. Free to Use →